Clinical Trial Update: Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating axitinib with or without the anti-OX40 antibody PF-04518600 for metastatic renal cell carcinoma, currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• PF-04518600 (anti-OX40 antibody) (PF-04518600)

Snippet

Sponsor: University of Southern California | Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING